A Huanguo mourns. It lasted for nearly half a month. In the past half a month, the TV shows are basically documentaries that were only made before the broadcast, such as the introduction of the old man's life. From an early age to the period until later he embarked on the post of supreme leader. The ups and downs of the past few decades have appeared one by one in more than a dozen episodes of documentaries.

As a person with a very close relationship with the elder's family, Fan Wubing naturally also participated in the memorial activities held later, especially after following the leader of the Politburo, he laid a wreath as an important friend.

After dealing with matters here, Fan Wubing focused his energy on negotiating the acquisition with Haizhou Pharmaceutical Group. After a few months of desalination. Fan Wuyi and Donghai Province came up with a solution. Bypassing the supervision of the central ministries and commissions, the research department of the Haizhou Pharmaceutical Group was recorded first. The Haizhou New Drug Research Institute was established, which was independently controlled by the government. Since then, the Haizhou Pharmaceutical Group's research department has been established separately.

After that, Fan Investment Group reached a cooperation agreement with Donghai Province. Fan Investment Group invested 100 million yuan and obtained 80% of the shares of the Institute. Since then, it has become the main group of 500 people with doctoral and master's degrees. The new boss of the drug research institute established by the skeleton.

Because this case did not rise to the level of directly acquiring Haizhou Pharmaceutical Group, it bypassed the supervision of the central ministries and commissions, and waited until the opposition to Fan Investment Group’s acquisition of Haizhou Pharmaceutical Group recovered. , The tree has just come to an end, and in this matter, except for some criticisms on the operation method, there is no suspicion of violation of regulations, so the main body of the Haizhou Pharmaceutical Group has not moved. What Fan Investment Group acquired is only a small part of the professional institutions that have been separated by the Donghai Provincial Government.

Moreover, the price of this small-scale acquisition is quite high. After all, not only does the research institute have no profitability, but also needs to invest a lot of money every year to maintain its operation. It can be said that it is very important for the entire Haizhou Pharmaceutical Group. Words are a big burden.

Before this, many people from Haizhou Pharmaceutical Group said that the company has so many researchers, but they have not produced any decent research results. On the contrary, large research expenses and personnel expenditures will cause Haizhou Pharmaceutical Group. It was too overwhelmed and overwhelmed, so some people wanted to abolish the research department. The company had proposed this for us, but the group has been afraid to take action. I'm afraid something big will happen.

After all, the layoffs in the past two years caused a lot of emotions that affected local stability. At this time, from corporate leaders to local leaders, under normal circumstances, they are unwilling to touch the interests of this area.

At this time, Fan Wu was sick; the leaders of Donghai Province, especially the governor Wu Fukuan, who was eager to move closer to the Fan family, immediately made a decision. Respect the previous opinions of Haizhou Pharmaceutical Group, separate the research department, and follow the path of market-oriented operation. The government and Fan Investment Group will jointly establish a joint-stock research institute. The benefits produced will also be divided by the two according to the proportion of equity. .

However, Fan's Investment Group also stated that as new funds are continuously injected into the research institute, the proportion of shares held by the Donghai Provincial Government in the research institute will be correspondingly diluted.

"That is to say, if Fan's capital injection exceeds 1 billion, the Donghai Provincial Government's share of the research institute will be less than 2%?" After Shen Ying learned of the news, he asked Fan Wu The disease asked. "It seems that you are determined to win this research department."

"That's natural, Fan Wubing nodded and replied, "In fact, what I really care about is the research team of the Haizhou Pharmaceutical Group. After all, this team is still very powerful. It was just limited to the relationship between the system and did not play its due role. Now that it has been stockized, I can use him to do many things. "

There are many good things in Fan Wubing's hands, such as the secret recipe given to him by teacher Fan Tianlan. These things can all be commercialized. Let them become new drugs that are more conducive to promotion, but to turn traditional Chinese medicine preparations into tablets or capsules, oral liquids, etc. that are suitable for the current market needs, it needs to be repositioned. And make some pathological tests and toxicity analysis. Or there are various test requirements that need to meet the requirements of the International Organization for Standardization. In the end, a result can be obtained that allows the new drug to be promoted in the market.

All of this requires a professional research team to do it, not the ability of one or two people can do it.

Fan Wubing rushed to do new drug research and promotion work, mainly because he felt the huge pressure of European and American drugs, and wanted to make the domestic drug market break a **** way and regain many lost traditional drug markets.

In recent years, it is generally believed. In terms of drug research capabilities, the United States has eclipsed Europe. However, based on the analysis of all data in the past two decades, in terms of drug innovation, the United States has not surpassed Europe in the research efficiency of new drugs, and European new drug research capabilities are still ahead of the United States. Compared with the new drugs previously prescribed. The clinical efficacy of most new drugs has not increased significantly.

Official and industry reports once generally believed that the United States had already passed Europe in terms of prescribing new drugs. But even though the U.S. Congress and a large number of investors are encouraging pharmaceutical companies to start and sell new drugs. And these new drugs have no real value, and the curative effect of the new drugs is only slightly compared with the old drugs.

The United States has shown rapid development in the research of global drugs, innovative drugs, biological products and orphan drugs, but the research capacity of Europe has hardly decreased, and Europe is still leading in terms of openings and global high profits.

Obviously, the United States did not have Europe in terms of new compounds.

Pharmaceutical research capabilities and total research investment are often confused. A very typical propaganda has been since two thousand years. The United States has developed itself as a major innovator in pharmaceuticals. This statement stems from the fact that the United States has invested more funds in research departments, but it is still unknown how many genuine new products there are in American laboratories.

And many responsible experts say that the conclusion that most new drugs are high-quality or important to patients is also untenable.

From the perspective of patients, doctors, and health policy, quality means that new drugs are clinically more effective or have fewer side effects than existing drugs. However, many current survey reports do not use data or treatment results to evaluate the quality of new drugs. The advertisements of some new drugs have clearly misled consumers and promoted that the new drugs are effective. Judging from the clinical benefits of the patients taking the drugs. The curative effect of the two is almost

In short, commercial success often does not equate to a significant improvement in efficacy.

For now. It is true that domestic companies need to encourage companies to prescribe new drugs with better efficacy than existing drugs. Instead of prescribing a medicine that is only a little better than a placebo. Therefore, some scholars suggest that independent clinical trials should be sponsored by public institutions such as the National Institutes of Health in the United States. In this way, advantages and risks can be compared with existing treatment methods. Publicly sponsored trials can also reduce costs and risks for manufacturers, and improve the research capabilities and competitiveness of small factories by reducing high-cost barriers.

"Now the government has completely liberalized the approval of new drugs. I am afraid that there are no less than 20,000 new drugs that come out every year, but among them, they can really be called new drugs. I am afraid that there are not even a hundred. Others It was just some old drugs that were put on the market under a new name after changing their packaging. Fan Wuyao mentioned this problem. He said to Shen Ying, “For example, those drugs that often appear in TV commercials. In fact, it is an upgraded version of a very simple cold granule, or simply the same thing has changed the packaging method. Not only has there been no improvement in efficacy, or has been reduced, but the price is several times or dozens higher than the original product. This is very unfavorable for consumers who don’t know the truth. "

Fan Wubing is very clear that for the current domestic innovative drug research companies, such as insufficient attention, insufficient investment, and failure to keep up with basic research, this situation must be changed. Relying on the government is not enough, and you can only do something yourself.

In order to be among the world's advanced in the research and production of innovative drugs, we must first create a group of outstanding talents. Including excellent technical personnel and management personnel. Therefore, the first thing that should be solved is the issue of incentive mechanism for scientific research personnel engaged in application foundation and development, and explore the options and equity issues of scientists when intangible assets become shares. It mainly includes scientific research personnel in scientific research institutes and enterprises.

After all, the research of innovative drugs will eventually go to the regular field. In addition to the need for excellent technical personnel, an excellent management team must also be created.

In addition to solving the problem of talents, it is necessary to strengthen basic research to lay a solid foundation for the successful research of innovative drugs. Almost all governments in Darfur have used their main funds to support basic research, while the funding for applied basics and research is mainly invested by enterprises, and this is also true for the research of innovative drugs.

However, due to many reasons such as system and mechanism in China, state-owned and state-holding enterprises that currently dominate are difficult to become the main innovation entities. Under normal circumstances. At present, the strength of such companies to spend huge sums of money on original innovative drug research is still insufficient.

So at this stage. It is necessary to set up some major industrialization projects to support the industrialization of the achievements accumulated over the years of various research institutes as soon as possible. And with the universal and effective establishment of modern corporate systems. As a group of enterprises have increased their investment strength, they will surely become the mainstay of technological innovation, which is also inevitable.

Now Fan Wuyao is just taking this path ahead of time, in order to increase the research strength of domestic innovative drugs as soon as possible, so as not to lag behind foreign counterparts too much.

New technologies have become the starting point and an indispensable part of new drug research. Tracking leading-edge key technologies is very important for the research of innovative drugs. Based on the latest achievements of the human genome, it integrates molecular biology, structural biology, computer-assisted virtual screening, combinatorial chemistry and high-throughput screening and other drug research high-tech technologies. It is a good idea to establish a platform for innovative drug discovery and practice in a variety of target protein systems related to important diseases.

New drug research is actually a set of systems engineering that guides the establishment of a high-tech platform for concentrated creation of new drugs and the formation of a research group composed of high-level interdisciplinary researchers, perfecting the innovative drug research system, and strengthening the construction of a key bottleneck technology platform. Such as preparation technology, pharmacy platform, etc., this is not a problem that current state-owned enterprises can solve.

But what followed was a little bit dumbfounding. After seeing that Fan Investment Group did not seem to have much interest in acquiring Haizhou Pharmaceutical Group, the cadres and employees of Haizhou Pharmaceutical Group were very disappointed. After all, everyone is very clear about the current situation of Haizhou Pharmaceutical Group. If we do not introduce strategic investors, it will soon be unable to sustain it.

The so-called annual sales exceeding tens of billions are just talking, at this time the group's profits have been declining. The debt ratio has been rising. If there is no breakthrough, everyone will go to the northwest wind next year.

When the Fan Investment Group had the intention to acquire, the employees of Haizhou Pharmaceutical Group were very willing, because everyone has known that the living standards of the employees of the major companies acquired by Fan are now If the Haizhou Pharmaceutical Group is successfully acquired by Fan's, which has an advantageous position in the local area, there will be no exceptions.

However, no one thought that this acquisition case was stopped by the central ministries and commissions, and everyone’s thoughts were turned into a bubble~lightnovelpub.net~ It was really unacceptable. Seeing that the most invisible research department of the group gave it to you. Many people are happy to go out alone, thinking that they have finally thrown out a big burden.

But Fan's Investment Group actually acquired the independent Haizhou New Drug Research Institute. This is another surprise. Compared with the New Drug Research Institute, which requires a large amount of investment support funds, production companies can directly generate part of the income? !

Fan's thoughts. It's always unpredictable.

However, after confirming through internal relations that Fan was no longer interested in the acquisition of Haizhou Pharmaceutical Group, most of the employees of Haizhou Pharmaceutical Group felt a little angry, thinking that the inaction of the central ministries and commissions caused them to face risks. If Haizhou Pharmaceutical Group goes bankrupt next year because of this, wouldn’t all of them be laid off?

Although the leaders can get away beforehand and take up positions in different places, how can they survive? As already specialized technical workers, they are actually the lowest level of existence in this society. What kind of jobs can they find without a company that they can work for?

Therefore, the employees of Haizhou Pharmaceutical Group organized a petition team of up to two hundred people and went directly to the capital, of course. The banner that came out was tourism group. To be continued)